EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use

Amy M VandenBerg iD

Mental Health Clinician · 01.10.2022 · 12 (5) · 270-281

DOI: 10.9740/mhc.2022.10.270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mental Health Clinician, online erschienen am 03.11.2022. Verfasst von Amy M VandenBerg. Beteiligte Einrichtung: Clinical Associate Professor, University of Michigan College of Pharmacy, Ann Arbor, Michigan, amberg@med.umich.edu. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 decades of use, key aspects have been well studied, including population pharmacokinetics, CYP interactions and various clinical and economic outcomes. However, there are still unknowns with these medications. Issues including adherence, transition from oral antipsychotics, renal dosing, pharmacogenomics, and managing missed doses will be addressed in the context of 4 patient cases.

Schlagwörter

Stichwörter der Autor:innen

aripiprazolebipolar disorderlong-acting injectable antipsychoticpaliperidonerisperidoneschizophrenia

Autor:innen und Institutionen

  • Clinical Associate Professor, University of Michigan College of Pharmacy, Ann Arbor, Michigan, amberg@med.umich.edu.

ORCID-Profile: Amy M VandenBerg

Zitieren

APA

VandenBerg, A. M. (2022). An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Mental Health Clinician, 12(5), 270-281. https://doi.org/10.9740/mhc.2022.10.270

Vancouver

VandenBerg AM. An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Mental Health Clinician. 2022;12(5):270-281. doi:10.9740/mhc.2022.10.270

BibTeX
@article{VandenBerg2022,
  author = {VandenBerg, Amy M},
  title = {An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use},
  journal = {Mental Health Clinician},
  year = {2022},
  volume = {12},
  number = {5},
  pages = {270--281},
  doi = {10.9740/mhc.2022.10.270}
}
Kostenlos starten →